This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Enhancing Effect of Interleukin 1 Administration on Antitumor Effector T-Cell Development

Vernon K. Sondak, MD; Melissa K. Tuck, MS; Suyu Shu, PhD; Hirohisa Yoshizawa, MD; Alfred E. Chang, MD

Arch Surg. 1991;126(12):1503-1509.

Abstract
• Antitumor effector T cells can be generated from tumordraining lymph node cells by activation with anti-CD3 monoclonal antibody and interleukin 2. Fresh tumordraining lymph node cells do not have antitumor activity, but after anti-CD3 monoclonal antibody–interleukin 2 activation, these cells mediate immunologically specific tumor regression in vivo. We examined the effect of interleukin 1 administration on the development of effector T cells derived from tumor-draining lymph nodes. Mice were inoculated with tumor cells, and interleukin 1 (180 to 720 ng) was administered on days 0, 2, and 4. Tumordraining lymph nodes harvested 10 to 14 days later were activated in anti-CD3 monoclonal antibody for 2 days followed by expansion in interleukin 2 for 3 days. Antitumor efficacy of the activated cells was assessed in the adoptive immunotherapy of lung micrometastases. Administration of interleukin 1 enhanced the antitumor reactivity of effector cells derived from tumor-draining lymph nodes without changing the immunologic specificity of the cells. Administration of interleukin 1 did not alter the phenotype of fresh or activated tumor-draining lymph node cells. Interleukin 1 deserves further investigation as an immune adjuvant in adoptive immunotherapy.

(Arch Surg. 1991;126:1503-1509)

Author Affiliations
From the Division of Surgical Oncology, Department of Surgery, University of Michigan Medical Center, Ann Arbor.

Footnotes
Accepted for publication August 3, 1991.

Read before the 44th Annual Cancer Symposium of the Society of Surgical Oncology, Orlando, Fla, March 27, 1991.

Reprint requests to Division of Surgical Oncology, 2920 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, Ml 48109-0331 (Dr Sondak).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?